Haemophilia and bleeding disorders

Links to the Summary of Product Characteristics (SmPC) and Patient Information Leaflets (PIL) for Novo Nordisk's range of diabetes products are available in this section.

NovoEight® (turoctocog alfa) PIP Code
NovoEight® 250 IU
402-7744
PIL
NovoEight® 500 IU 402-7751
PIL
NovoEight® 1000 IU 402-7769
PIL
NovoEight® 1500 IU 402-7777
PIL
NovoEight® 2000 IU 402-7785
PIL
NovoEight® 3000 IU 402-7793
PIL
 
   
Summary of Product Characteristics - Click here

NovoSeven® (eptacog alfa activated)

PIP Code

NovoSeven® 1mg

377-1672
PIL

NovoSeven® 2mg

377-1680
PIL

NovoSeven® 5mg

377-1698
PIL

NovoSeven® 8mg

377-1760
PIL
   
Summary of Product Characteristics - Click here

Refixia®    (nonacog beta pegol) PIP Code

Refixia®     500 IU 

 408-2632
PIL		  

Refixia®     1000 IU 
 		 408-2616
PIL		  

Refixia®     2000 IU 
 		 408-2624
PIL		  
     
Summary of Product Characteristics - Click here

Esperoct®  (turoctocog alfa pegol) PIP Code    
Esperoct®    500 IU 415-4167
PIL
Esperoct®   1000 IU 415-4175
PIL
Esperoct®   1500 IU
 415-4183
PIL
Esperoct®   2000 IU 415-4191
PIL
Esperoct®   3000 IU 415-4951
PIL
   
Summary of Product Characteristics - Click here

Reporting of side effects

 

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.  

Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 600 5055).  Calls may be monitored for training purposes.

  This medicine is subject to additional safety monitoring.  This will allow quick identification of new safety information.  You can help by reporting any side effects you may get.  See mhra.gov.uk/yellowcard for how to report side effects.

This page is intended for members of the UK public